United Therapeutics Corporation
Could not find a ticker for this position, may be a filing error
A maker of medicines for rare lung conditions such as pulmonary arterial hypertension, sold under brands like Remodulin and Tyvaso. Founder Martine Rothblatt launched the company in 1996 after her young daughter was diagnosed with the disease, turning a personal fight into a career. The firm is also known for a futuristic goal: gene-edited pig organs for human transplants, an approach that has made it a familiar name in xenotransplantation.
1.00% Convertible Senior Notes due 2016-09-15 (Rule 144A)
Granted 905.6K · Sold 856.6K
Granted 91.4K · Sold 74.7K
Granted 33.4K
Granted 4.0K · Sold 4.0K
Granted 288.2K · Sold 268.8K
Granted 4.9K · Sold 4.9K
Sold 258
Sold 600
Granted 1.3K · Sold 1.3K
Granted 3.9K · Sold 3.9K
Sold 95
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rothblatt Martine AChairperson & CEO, Director · 1089 transactions | +340.4% | 49.6K | 905.6K | — | 856.6K |
| Mahon Paul AEVP & GENERAL COUNSEL · 93 transactions | +0.2% | 45.2K | 91.4K | — | 74.7K |
| Benkowitz MichaelPRESIDENT AND COO · 4 transactions | +1277% | 36.5K | 33.4K | — | — |
| Thompson Tommy GDirector · 6 transactions | +3.7% | 30.3K | 4.0K | — | 4.0K |
| Edgemond JamesCFO AND TREASURER · 342 transactions | +182.8% | 25.5K | 288.2K | — | 268.8K |
| Kurzweil RayDirector · 2 transactions | +38.8% | 17.6K | 4.9K | — | 4.9K |
| Mesa NildaDirector · 1 transaction | -4.9% | 5.0K | — | — | 258 |
| Olian Judy D.Director · 3 transactions | -12.4% | 4.2K | — | — | 600 |
| Causey ChristopherDirector · 4 transactions | 0% | 4.2K | 1.3K | — | 1.3K |
| Patusky ChristopherDirector · 4 transactions | 0% | 2.6K | 3.9K | — | 3.9K |
| Malcolm JanDirector · 2 transactions | -43.2% | 125 | — | — | 95 |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -1.22M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.